Find, compare & contact
Fingolimod
API Manufacturers & Suppliers
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Producer
Produced in:
Established in: 1989
MOQ: -
Employees: 5000+
6 production facilities approved by USFDA, AGES-Austria, PMDA, WHO
R&D Centers with capabilities of ANDAs, DMFs and NDDS
462+ patents filed for drug substances and polymorphs
+ 0
All certificates
Producer
Produced in:
Established in: 2013
MOQ: 1 g
Employees: 25+
ISO9001 certified
Drug R&D center (in Hangzhou)
From lab scale (mg/g) to commercial scale (kgs/tons)
+ 0
All certificates
Professionalism: 20 years of experiences in pharma
Responsibility: One-step supply solution
Reliability: Considerate after-sales service
+ 0
All certificates
Producer
Produced in:
Established in: 2021
MOQ: -
Employees: 19
API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides
Small quantity APIs to commercial scale
GMP and USFDA certification based on quantity, order, assignment.
+ 0
All certificates
Producer
Produced in:
Established in: 2019
MOQ: 1 kg
Employees: 10+
Focused on pharmaceutical industry
Reasonable price for the customers
Full service from R&D stage to commercial stage
+ 0
All certificates
Distributor
Produced in:
Established in: 2005
MOQ: -
Employees: 200+
Portfolio of over 2,000 APIs
Precise quality control
End-to-end global regulatory support
+ 0
All certificates
Producer
Produced in:
Established in: 1944
MOQ: -
Employees: 4,000
14 international API plant sites
Portfolio of 350+ APIs
Teva is among the world’s largest generic drug/API manufacturers
+ 0
All certificates
Producer
+ 0
All certificates
Distributor
Produced in:
Established in: 1963
MOQ: -
Employees: 800+
World’s 1st exclusive API distributor
Portfolio of 600+ APIs
>250 clients in Europe
+ 0
All certificates
Producer
Produced in:
Established in: 1984
MOQ: -
Employees: 21,650
Diverse portfolio of 180+APIs
1754+ DMF across global markets
1100+ patents filed, and more than 70 own patents granted
+ 0
All certificates
Producer
Produced in:
Established in: 1995
MOQ: -
Employees: 10000
Fermentation technology Experts
Partnerships with 1200 pharma companies in 100+ countries
US FDA, EMA, COFEPRIES, ANVISA, PMDA accreditations
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Fingolimod API 162359-55-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Fingolimod. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fingolimod
- Synonyms:
- Fingolimodum , Fingolimod HCl , Fingolimod hydrochloride
- Cas Number:
- 162359-55-9
- DrugBank number:
- DB08868
- Unique Ingredient Identifier:
- 3QN8BYN5QF
About Fingolimod
Learn more about Fingolimod. Multiple sclerosis or MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010.
Check who is selling Fingolimod in the overview above.
Fingolimod is a type of Immunosuppressants
Immunosuppressants are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in medical treatments. These substances are designed to suppress or weaken the immune system's response, making them invaluable in various therapeutic applications.
Immunosuppressants find extensive use in the management of autoimmune diseases, organ transplantation, and the prevention of rejection reactions. By modulating the immune system's activity, these APIs help control excessive immune responses that can lead to tissue damage and chronic inflammation.
There are different classes of immunosuppressants, including corticosteroids, calcineurin inhibitors, antimetabolites, and biologics. Each class targets specific immune pathways to achieve the desired therapeutic effect. Corticosteroids, for instance, are known for their potent anti-inflammatory properties, making them effective in managing conditions such as rheumatoid arthritis and asthma.
Calcineurin inhibitors like cyclosporine and tacrolimus act by inhibiting the activity of calcineurin, a protein involved in immune cell activation. These drugs are commonly used in organ transplantation to prevent the immune system from attacking the transplanted organ.
Antimetabolites interfere with DNA synthesis and cell proliferation, thereby dampening immune responses. They are often prescribed for conditions like psoriasis and rheumatoid arthritis.
Biologic immunosuppressants, such as monoclonal antibodies, target specific immune cells or molecules involved in the disease process. They have revolutionized the treatment of autoimmune diseases like rheumatoid arthritis, Crohn's disease, and psoriasis.
Immunosuppressants require careful administration and monitoring due to their potential side effects and interactions with other medications. Close collaboration between healthcare professionals, pharmacists, and patients is essential to ensure the safe and effective use of these APIs in various therapeutic settings.
Overall, immunosuppressants represent a critical category of pharmaceutical APIs that significantly contribute to improving patients' quality of life by controlling the immune system's activity and managing various autoimmune conditions and transplantation outcomes.
Fingolimod (Immunosuppressants), classified under Immunomodulators
Immunomodulators, a category of pharmaceutical active pharmaceutical ingredients (APIs), are substances that help regulate and modify the immune response of an individual. These compounds play a crucial role in treating various immune-related disorders and diseases. Immunomodulators work by either enhancing or suppressing the immune system, depending on the specific condition being treated.
Immunomodulators are used in the treatment of autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, and psoriasis. By suppressing the immune system, these APIs help reduce the overactive immune response associated with these conditions, thereby alleviating symptoms and preventing further damage to the body's tissues.
On the other hand, immunomodulators are also employed to boost the immune system in cases of immunodeficiency disorders. These APIs stimulate the immune response, enabling the body to better fight off infections and diseases. Additionally, immunomodulators are utilized in the prevention and treatment of organ transplant rejection, where they help modulate the immune system to accept the transplanted organ.
The development and production of immunomodulators require rigorous testing and quality control to ensure their safety and efficacy. Pharmaceutical companies carefully formulate these APIs into various dosage forms, including tablets, capsules, injections, and topical preparations, to cater to different patient needs.
In summary, immunomodulators form a vital category of pharmaceutical APIs that regulate and modify the immune system. With their ability to modulate immune responses, these compounds contribute significantly to the management and treatment of various immune-related disorders and diseases, improving the quality of life for many patients.
Fingolimod manufacturers | traders | suppliers
We have 18 companies offering Fingolimod produced in 5 different countries.
Get in contact with the supplier of your choice:
- Shilpa Medicare Ltd from India, product country of origin India
- Senova Technology Co., Ltd. from China, product country of origin China
- Changzhou Comwin Fine Chemicals Co., Ltd from China, product country of origin China
- SETV Global from India, product country of origin India
- Apino Pharma Co., Ltd. from China, product country of origin China
- LGM Pharma from United States, product country of origin World
- Teva API from Israel, product country of origin Unknown
- Intas Pharma from United Kingdom, product country of origin Unknown
- TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
- Dr. Reddy's from India, product country of origin India
- Biocon from India, product country of origin India
- HEC Pharm from Germany, product country of origin Unknown
- Maprimed from Argentina, product country of origin Argentina
- Honour Lab from India, product country of origin India
- Mylan from India, product country of origin India
- Emcure Pharma from India, product country of origin India
- MSN Labs. from India, product country of origin India
- Sun Pharma from India, product country of origin India
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.